Cantargia

About:

Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.

Website: http://www.cantargia.com

Top Investors: Sunstone Life Science Ventures, Lubio Science

Description:

The company is based on the original discovery that leukemic stem cells in patients with chronic myeloid leukemia (CML) express a cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. Stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) has also been shown to have and upregulation of the receptor. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia